CNBC December 11, 2024
Key Points
– Direct-to-consumer health-care startup Ro said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly.
– Ro will offer a “complete end-to-end” experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug delivered to their homes.
– That is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, LillyDirect, and aims to streamline access to the popular treatment.
Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly,...
Today's Sponsors
Today's Sponsor